In an elderly patient with cardiovascular disease, should furosemide be preferred over amlodipine, and in an elderly patient without cardiovascular disease, should amlodipine be preferred?

Amlodipine is the preferred agent in elderly patients regardless of cardiovascular disease status; furosemide is not a first-line antihypertensive and should be reserved for specific indications like volume overload.

Elderly Patients WITH Cardiovascular Disease

Amlodipine should be the preferred choice over furosemide for blood pressure management in elderly patients with cardiovascular disease. Multiple international guidelines consistently recommend calcium channel blockers (specifically dihydropyridine CCBs like amlodipine) as first-line therapy for hypertension in the elderly 1, 2. The 2007 ESH/ESC guidelines explicitly state that "drug treatment can be initiated with thiazide diuretics, calcium antagonists, angiotensin receptor antagonists, ACE inhibitors, and β-blockers" in elderly patients, with trials specifically addressing isolated systolic hypertension demonstrating benefit of thiazides and calcium antagonists 2.

Key evidence supporting amlodipine:

• The 2024 ESC guidelines recommend ACE inhibitors, ARBs, dihydropyridine CCBs, and diuretics as first-line treatments that have demonstrated the most effective reduction of BP and cardiovascular events 3
• Amlodipine has proven efficacy in elderly populations with cardiovascular disease, reducing morbidity and mortality 4, 5
• The drug is well-tolerated in elderly patients and can be prescribed in the presence of comorbid conditions 4

Furosemide's limited role:

• Furosemide is NOT recommended as a first-line antihypertensive agent 6
• Loop diuretics like furosemide should be used "promptly when congestion is present" but reduced or discontinued once euvolemia is achieved 7
• The FDA label indicates furosemide is primarily for edema management, with hypertension treatment requiring 80mg daily (usually divided into 40mg twice daily) 6
• Recent data shows furosemide is overused in elderly patients, particularly the very elderly, and is associated with increased fall risk when combined with amlodipine 8, 9

Elderly Patients WITHOUT Cardiovascular Disease

Amlodipine remains the superior choice for uncomplicated hypertension in elderly patients without cardiovascular disease. The Canadian Hypertension Education Program (2013) specifically recommends for isolated systolic hypertension: "Initial therapy should be monotherapy with a thiazide diuretic (Grade A), a long-acting dihydropyridine CCB (Grade A), or an ARB (Grade B)" 1.

Supporting rationale:

• The British Hypertension Society guidelines identify "isolated systolic hypertension in elderly patients" as a compelling indication for dihydropyridine calcium channel blockers 10
• Amlodipine demonstrates significant blood pressure reduction in patients ≥55 years: systolic BP decreased by 12.1 mmHg and diastolic BP by 6.7 mmHg, with 39.3% achieving BP goals 11
• The 2020 ISH guidelines recommend starting with low-dose ARB/ACEI or DHP-CCB, then adding the other class if needed 12

Why NOT furosemide:

• Furosemide has no role as first-line therapy for uncomplicated hypertension in elderly patients
• The drug carries significant risks in elderly populations including hypotension, renal dysfunction, electrolyte instability, falls, and cognitive impairment 7
• A 2023 study found furosemide ranked 10th in prescriptions for old patients but jumped to 3rd for very old patients (5.5% of prescriptions), suggesting inappropriate overuse 8
• When amlodipine and furosemide are prescribed together, there is a significantly increased fall risk (OR = 2.5 for orthostatic hypotension-inducing drugs) 9

Critical Clinical Pitfalls

Common prescribing errors to avoid:

1. Using furosemide for blood pressure control: Furosemide is for volume management, not primary hypertension treatment
2. Combining amlodipine with furosemide unnecessarily: This combination increases fall risk (patients had 2.8 vs 1.3 orthostatic hypotension-inducing drugs) 9
3. Continuing furosemide long-term without reassessment: Loop diuretics should be reduced or discontinued once euvolemia is achieved 7
4. Starting with high doses in elderly: Initial doses should be more gradual in elderly patients due to greater chance of adverse effects 2

Practical Treatment Algorithm

For elderly patients (≥60 years) with OR without cardiovascular disease:

1. Start with amlodipine 5mg daily (can be increased to 10mg if needed) 13, 11
2. Monitor for peripheral edema (common side effect of amlodipine)
3. If edema develops AND there is objective volume overload:
   • Add furosemide at lowest effective dose (20-40mg daily) 6
   • Reassess weekly with weight, urine output, renal function, and electrolytes
   • Reduce or discontinue furosemide once euvolemia achieved 7
4. If BP not controlled with amlodipine alone:
   • Add ACE inhibitor/ARB or thiazide-like diuretic (NOT furosemide) 1, 3
   • Preferred combinations: amlodipine + ACE inhibitor/ARB or amlodipine + thiazide 14, 3

Special considerations for very elderly (≥80 years):

• Target BP <150/90 mmHg (less stringent than younger elderly) 1
• Start at lower end of dosing range
• Monitor closely for orthostatic hypotension (measure BP in erect posture) 2

The evidence overwhelmingly supports amlodipine as first-line therapy for elderly hypertensive patients regardless of cardiovascular disease status, while furosemide should be reserved exclusively for managing volume overload with clear stopping criteria once congestion resolves.